First-in-Human Phase I Trial of TQ-B3139 in Patients With NSCLC With ALK and ROS1 Rearrangements
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
European Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements
Eur. J. Cancer 2022 Sep 01;173(xx)238-249, Y Ma, H Zhao, J Xue, L Liu, N Yang, Y Zhang, H Yang, S Hong, Y Xiong, Z Zhang, L Zeng, H Pan, C Zhou, Y Zhang, X Wang, X Han, X Wan, Y Shao, J Liu, Y Yang, Y Huang, Y Zhao, W Fang, S Li, L ZhangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.